BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-489@pharmaconomics
DTSTAMP:20260707T021802Z
DTSTART;VALUE=DATE:20260622
DTEND;VALUE=DATE:20260623
SUMMARY:MPLT Phase 2 — ML-004
DESCRIPTION:Phase 2 trial results for ML-004 in autism spectrum disorder are due Jun 22\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1770069/000119312526276691/d31456d8k.htm\n\nTrack it: https://www.pharmaconomics.com/e/489
URL:https://www.pharmaconomics.com/e/489
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:MPLT catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR